NCT05490095View on ClinicalTrials.gov

Randomized Crossover of SVG101(Dispersible Tab. of Everolimus) and Afinitor 5mg in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

July 23, 2021

Primary Completion Date

January 28, 2022

Study Completion Date

February 7, 2022

Conditions
Pharmacokinetics
Interventions
DRUG

SVG101 (T)

5mg of SVG101

DRUG

Afinitor (R)

5mg of Afinitor

Trial Locations (1)

Unknown

Yonsei University Healthcare System, Severance Hospital, Seoul

All Listed Sponsors
lead

SoVarGen Co., Ltd.

INDUSTRY

NCT05490095 - Randomized Crossover of SVG101(Dispersible Tab. of Everolimus) and Afinitor 5mg in Healthy Adults | Biotech Hunter | Biotech Hunter